Loading clinical trials...
Loading clinical trials...
Open Label Treatment of Beremagene Geperpavec (B-VEC)
Conditions
Interventions
Open Label Topical Beremagene Geperpavec (B-VEC)
Locations
6
United States
Mission Dermatology Center
Rancho Santa Margarita, California, United States
Stanford University
Redwood City, California, United States
Pediatric Skin Research
Coral Gables, Florida, United States
Northwestern University
Chicago, Illinois, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Ascension Seton- Dell's Children Medical Group
Austin, Texas, United States
Start Date
May 25, 2021
Primary Completion Date
July 31, 2023
Completion Date
July 31, 2023
Last Updated
April 9, 2024
NCT05157958
NCT04213261
NCT06892639
NCT06713434
NCT05725018
NCT07011589
Lead Sponsor
Krystal Biotech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions